Tirzepatide 10 mg

$188.00

Size

Order total:
Tirzepatide 10 mg $188.00
Guaranteed Safe Checkout

Product Name: Tirzepatide

CAS No: 2023788-19-2

CAT No: P100130

Molar Mass: 4813.45

Chemical Formula: C225H348N48O68

Synonyms: LY 3298176, BG 121, Tirzepatide

Storage: Store at -20°C

Sequence: YXEGTFTSDY SIXLDKIAQK AFVQWLIAGG PSSGAPPPS

Target Indicators: GLP-1 RA

Purity: 98%

Application:

Tirzepatide (CAS: 2023788-19-2) stands out as a breakthrough in pharmaceutical innovation, particularly in the realm of diabetes treatment. As a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, tirzepatide exerts its action by stimulating insulin release and inhibiting glucagon secretion. The dual agonism enhances glycemic control effectively, making it a promising therapeutic option for individuals with type 2 diabetes. This innovative compound targets both GIP and GLP-1 receptors, regulating glucose metabolism with a focus on postprandial and fasting hyperglycemia. Tirzepatide’s potential extends beyond glycemic control, showing promise in weight management, an essential aspect of diabetes care. Its versatility positions tirzepatide as a pivotal player in advancing pharmaceutical interventions for metabolic disorders, offering a comprehensive approach to address the complex interplay of factors in diabetes management.

Current Research:

Tirzepatide, a novel once-weekly dual receptor agonist targeting both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has emerged as a promising therapeutic option for addressing the complex interplay between obesity and its associated comorbidities, particularly type 2 diabetes (T2D) and cardiovascular disease (CVD). The escalating global prevalence of obesity, accompanied by a myriad of serious complications such as T2D, hypertension, dyslipidemia, and CVD mortality, underscores the urgent need for effective obesity treatments to mitigate morbidity and mortality.

Recent advancements in anti-obesity pharmacotherapy, including long-acting GLP-1 receptor agonists, have demonstrated significant weight reduction and improvements in cardiovascular risk factors in individuals with obesity. Building upon this foundation, tirzepatide, with its unique dual agonism of GIP and GLP-1 receptors, holds immense promise for enhancing weight loss outcomes and addressing cardiometabolic risk factors associated with obesity.

Clinical trials, including the SURMOUNT-1 trial, have revealed substantial and sustained weight reduction with tirzepatide treatment in individuals with obesity or overweight, independent of diabetes status. Importantly, tirzepatide has shown favorable effects on cardiometabolic parameters, including blood pressure, lipid levels, and glycemic control, further supporting its potential as a comprehensive therapeutic approach for obesity-related complications.

A notable highlight of tirzepatide’s clinical profile is its significant reduction in the 10-year predicted risk of atherosclerotic cardiovascular disease (ASCVD) compared to placebo, as demonstrated in post hoc analyses of the SURMOUNT-1 trial. This reduction in ASCVD risk was particularly pronounced in participants with higher baseline ASCVD risk, emphasizing the potential of tirzepatide to address the heightened cardiovascular risk associated with obesity.

While the cardiovascular benefits of tirzepatide are encouraging, ongoing research endeavors, including large-scale phase 3 studies such as SURMOUNT-MMO and SURPASS-CVOT, aim to further elucidate its impact on cardiovascular outcomes in both individuals with obesity or overweight, with and without diabetes.

Despite the robustness of the findings from post hoc analyses, certain limitations inherent to such studies, including the relatively short duration of the trial and the low baseline ASCVD risk profile of participants, warrant cautious interpretation of the results. Nonetheless, the consistent and favorable outcomes observed

Reference:

Baker, D. E., Walley, K., & Levien, T. L. (2023). Tirzepatide. Hospital Pharmacy, 58(3), 227-243.

Hankosky, E. R., Wang, H., Neff, L. M., Kan, H., Wang, F., Ahmad, N. N., … & Garvey, W. T. (2024). Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT‐1 post hoc analysis. Diabetes, Obesity and Metabolism, 26(1), 319-328.


Get a Quote

Please enable JavaScript in your browser to complete this form.
Please input the Nmae
Please input the Email
Please input the organization
Please input the Phone
Address
Please specify your needs regarding the inquired product, e.g. it's purity, apperance, application, etc.